国投证券股份有限公司 关于 株洲千金药业股份有限公司发行股份及支付现金购 买资产暨关联交易 之标的资产过户情况的 独立财务顾问核查意见 独立财务顾问 二〇二五年九月 声明和承诺 国投证券股份有限公司（以下简称"本独立财务顾问"）受株洲千金药业股 份有限公司（以下简称"千金药业""上市公司"或"公司"）委托，担任其本次 发行股份及支付现金购买资产暨关联交易的独立财务顾问。 本独立财务顾问核查意见是根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务 管理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》等相关法律法规的规定，按照证券行业公认的业务标准、道德规 范，本着诚实信用、勤勉尽责的精神，遵循客观、公正原则，在认真审阅相关资 料和充分了解本次交易行为的基础上，本独立财务顾问出具了就上市公司本次资 产重组相关资产交割过户情况的核查意见，本独立财务顾问对本核查意见特作如 下声明： 1、本独立财务顾问核查意见所依据的文件和材料由本次交易各方提供，提 供方对所提供文件及资料的真实性、准确性和完整性负责，并保证该等信 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-048 一、本次交易的实施情况 （一）标的资产交割过户 截至本公告日，株洲国有资产投资控股集团有限公司（以下简称"株洲国投"）、 淮安列邦康泰化工有限公司（以下简称"列邦康泰"）合计持有的千金湘江药业 28.92%的股权以及株洲国投和黄阳等 21 名自然人合计持有的千金协力药业 68.00%的股权已过户至公司名下，本次交易涉及的标的资产交割过户手续已办理 完毕，公司已合法取得标的资产。 株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易之标的资产 过户情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"）拟通过发行股份及支付现 金方式购买湖南千金湘江药业股份有限公司 28.92%的股权及湖南千金协力药业 有限公司 68.00%的股权（以下简称"本次交易"）。 公司于 2025 年 9 月 12 日收到中国证券监督管理委员会出具的《关于同意株 洲千金药业股份有限公司发行股份购买资产注册的批复》（ ...

丨 2025年9月15日 星期一 丨 NO.1 百洋医药拟以24%股权战略投资济坤医药 百洋医药公告，公司与天津济坤医药签订战略合作协议，百洋医药战略投资济坤医药，拟持有其24%股 权，进而锁定济坤医药旗下用于治疗肺纤维化的1类创新药的所有权益。同时，公司对济坤医药持有的 所有产品的全球化合物权益享有同等条件下优先购买权。 每经记者｜甄素静 每经编辑｜张海妮 点评：华大基因控股股东华大控股拟转让4%股份，借询价转让获得资金，用于细胞组学、时空组学等 前沿科技孵化。此次布局或为华大基因开拓新增长曲线。 NO.4 索元生物在研新药关键性研究发表于《JAMA精神病学》 索元生物宣布，其关键性ENLIGHTEN试验成果以专题形式发表于精神病学顶级期刊《JAMA精神病 学》。研究结果显示，在携带新型药物基因组生物标志物ANK3的难治性抑郁症（TRD）患者中， DB104（Liafensine）展现出显著疗效。 点评：百洋医药战略投资济坤医药，锁定肺纤维化创新药JK1033项目权益，有望丰富创新药管线。叠 加其在肝纤维化领域的产品，可构建纤维化疾病治疗产品组合优势。 NO.2 千金药业：发行股份购买资产获同意批复 千金药 ...

Group 1 - Zhuzhou Qianjin Pharmaceutical Co., Ltd. received approval from the China Securities Regulatory Commission to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] - The transaction aims to enhance the control of Zhuzhou Guotou over the listed company, increasing its shareholding from 28.76% to 34.94%, which supports stable governance and control of the listed company [1] - The effects of policies such as the "Eight Articles for the Sci-Tech Innovation Board" and "Six Articles for Mergers and Acquisitions" are becoming evident, with 27 merger and reorganization projects accepted and 15 approved by the review committee since 2025, surpassing last year's total [1] Group 2 - The Shanghai Stock Exchange is focused on improving the efficiency of reorganization reviews, with several innovative and exemplary merger and reorganization cases being implemented, such as the mergers involving Silyus and Sanyou Medical [2] - Notable cases include the acquisition of Chiplink Integrated by Chiplink Yuezhou, the largest merger project in A-shares involving China Shipbuilding and China Shipbuilding Heavy Industry, and cross-industry mergers by Songfa Co. and cross-border mergers by Zhizheng Co. [2]

Group 1 - The stock price of Qianjin Pharmaceutical (600479) closed at 10.96 yuan on September 12, 2025, up 0.37% from the previous week [1] - The company's total market capitalization is 4.625 billion yuan, ranking 45th out of 67 in the traditional Chinese medicine sector and 3516th out of 5153 in the A-share market [1] - The highest intraday price reached 11.23 yuan and the lowest was 10.85 yuan on September 11, 2025 [1] Group 2 - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission (CSRC) for the issuance of shares to acquire assets, specifically 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [2] - The approval is valid for 12 months from the date of issuance, and the company must comply with the application documents submitted to the Shanghai Stock Exchange [2] - The company is required to fulfill information disclosure obligations and report any significant issues during the implementation process [2] Group 3 - The financial advisor, Guotai Junan Securities Co., Ltd., provided a continuous supervision opinion on the acquisition report, confirming that the acquirer and its concerted parties have complied with regulations [1][3] - There are no major adjustments planned for the acquirer's main business, asset restructuring, board or executive changes, employee hiring, dividend policies, or other significant plans during the supervision period [1][3]

千金药业(600479.SH)9月12日晚间发布公告称，公司计划以发行股份及支付现金的方式，收购湖南千金 湘江药业股份有限公司28.92%的股权以及湖南千金协力药业有限公司68%的股权。该公司于2025年9月 12日收到中国证监会下发的《关于同意株洲千金药业股份有限公司发行股份购买资产注册的批复》，证 监会已同意公司向特定对象发行5144.49万股股份以收购相关资产。公告同时指出，本次发行股份购买 资产需严格依照报送上海证券交易所的相关申请文件执行，并需在12个月内完成。（央广财经） ...

一、同意你公司向株洲市国有资产投资控股集团有限公司发行 51,444,886 股股份、向淮安市列邦康泰化工有限公司发行 617,667 股股份、向黄阳发行 7,536,982 股股份、向汤振军发行 4,598,216 股股份、向汤曜铭发行 2,299,108 股 股份、向唐闻伯发行 1,609,375 股股份、向邓汝腾发行 1,609,375 股股份、向叶胜 利发行 977,120 股股份、向刘金玉发行 739,807 股股份、向周莉华发行 646,624 股股份、向金亮发行 459,821 股股份、向张新民发行 359,235 股股份、向彭华军 发行 287,388 股股份、向王洪峰发行 215,541 股股份、向雷颖发行 86,216 股股份、 向丁四海发行 71,847 股股份、向刘军明发行 43,108 股股份、向陈积安发行 28,738 股股份、向罗斌发行 28,738 股股份、向殷文新发行 21,554 股股份、向吴永强发 行 14,369 股股份、向彭彩霞发行 7,184 股股份购买相关资产的注册申请。 二、你公司本次发行股份购买资产应当严格按照报送上海证券交易所的有关 申请文件进行。 证券代码 ...

Core Viewpoint - The company plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68.00% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1] Summary by Relevant Sections - The company received approval from the China Securities Regulatory Commission on September 12, 2025, for the issuance of 51,444,900 shares to specific investors for the asset acquisition [1] - The share issuance for asset acquisition must strictly follow the application documents submitted to the Shanghai Stock Exchange and is required to be completed within 12 months [1]

Market Overview - On September 12, the Chinese medicine sector declined by 0.56%, with Qianjin Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 10.25, up 3.64% on a trading volume of 228,400 shares and a turnover of 230 million yuan [1] - Jiuzhitang (000989) closed at 10.91, up 2.83% with a trading volume of 212,800 shares and a turnover of 233 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.07, up 2.48% with a trading volume of 4,321,600 shares and a turnover of 891 million yuan [1] - Conversely, significant decliners included: - Qianjin Pharmaceutical (600479) closed at 11.05, down 1.60% with a trading volume of 115,400 shares and a turnover of 128 million yuan [2] - Jianmin Group (600976) closed at 42.45, down 1.12% with a trading volume of 18,100 shares and a turnover of 77 million yuan [2] - Hansen Pharmaceutical (002412) closed at 6.74, down 1.03% with a trading volume of 133,300 shares and a turnover of 89 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 642 million yuan from institutional investors, while retail investors saw a net inflow of 448 million yuan [2] - The following stocks had notable capital flows: - Kangmei Pharmaceutical had a net inflow of 65.97 million yuan from institutional investors, but a net outflow of 14.99 million yuan from retail investors [3] - Jiuzhitang saw a net inflow of 33.21 million yuan from institutional investors, with a net outflow of 16.66 million yuan from retail investors [3] - Wanbangde had a net inflow of 30.43 million yuan from institutional investors, but also faced a net outflow of 19.37 million yuan from retail investors [3]

Core Points - Company will participate in the "2025 Hunan Listed Companies Investor Online Reception Day and Semi-Annual Performance Briefing" event [1] - The event aims to enhance interaction with investors and will be held online on September 19, 2025, from 14:00 to 17:00 [1] - Company executives will communicate about the company's performance and operational status for the first half of 2024 to 2025 [1] Event Details - The event is organized by the China Securities Regulatory Commission Hunan Supervision Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [1] - Investors can participate via the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [1] - The company encourages active participation from investors [1]